Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with rheumatoid arthritis
The results from the positive SIRROUND-D study are being presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.
-
ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
Agreement supports the first ‘Treat All’ programme for HIV in sub-Saharan Africa, where 70% of people with HIV live
-
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
Acceleration of filing of US New Drug Application now expected by end of 2016
-
Board and Committee changes
Dr Vivienne Cox, CBE, has been appointed to the Board of the Company as a Non-Executive Director with effect from 1 July 2016.
-
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID
GSK, Fondazione Telethon and Ospedale San Raffaele gain approval to provide life-saving gene therapy to patients.
-
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK today announced the publication in BLOOD of the long-term safety and efficacy data from an analysis of 18 children with ADA-SCID
-
Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice.
-
GSK presents new data from Breo® Ellipta® SUMMIT study in patients with COPD at ATS Conference
GSK presents new data at the American Thoracic Society Conference from two pre-specified analyses from the Study
-
GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium
GSK and Innoviva, Inc. announce results from data presented at the American Thoracic Society 2016 conference
-
GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal group B Vaccine (rDNA, component, adsorbed)]
-
European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries
Milestone for GSK and Save the Children partnership and its mission to help save the lives of children in the world’s poorest communities
-
Results announcement for the first quarter 2016
GSK delivers Q1 performance of £6.2 b (+8% CER), core EPS 19.8p (+8% CER); dividend of 19p 2016 core EPS growth expected to be 10-12% CER
-
GSK statement on pneumococcal vaccine pricing
For many years we have been working hard, in partnership with others, to develop vaccines against infectious diseases
-
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
Follows announcement by majority shareholder GSK to expand graduated approach to patents and intellectual property (IP)
-
GSK announces start of a phase II study to evaluate an anti GM-CSF antibody for inflammatory hand osteoarthritis
Phase II study evaluates efficacy and safety of an investigational anti-granulocyte macrophage colony-stimulating factor monoclonal antibody
-
GSK opens new state of the art respiratory manufacturing facility in Ware, UK
GSK today opens a £56 million state of the art manufacturing facility, creating 150 new jobs in the UK,
-
GSK receives positive CHMP opinion in Europe for Strimvelis™, the first gene therapy to treat very rare disease, ADA-SCID
GSK announces a positive opinion recommending marketing authorisation for Strimvelis
-
GSK expands graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries
GSK has a deep commitment to improving healthcare by developing innovative new medicines and widening access to them around the world.
-
GSK receives marketing authorisation for Nucala® (mepolizumab) in Japan
The Japanese Ministry of Health, Labour and Welfare has granted approval for Nucala® (mepolizumab) as a treatment for bronchial asthma.
-
Sir Andrew Witty to retire from GSK in March 2017
GSK plc today announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017